Abstract
Introduction:
VEGF promotes tumor angiogenesis and is an important target in various malignancies, including NSCLC.
Areas covered:
Here, the authors review the data that led to the approval of bevacizumab, a monoclonal antibody against VEGF, in the treatment of lung cancer. The authors also review the key results from a number of Phase II and Phase III trials involving other anti-angiogenic agents being studied in NSCLC, including small-molecule tyrosine kinase inhibitors against the VEGF-receptor and vascular-disrupting agents (VDAs).
Expert opinion:
Results from ongoing studies and the identification of reliable biomarkers remain critical goals in understanding the exact role of these anti-angiogenic agents in the treatment paradigm of NSCLC.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Animals
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Bevacizumab
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / metabolism
-
Protein Kinase Inhibitors / therapeutic use
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors*
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
-
Vascular Endothelial Growth Factor A / metabolism
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Protein Kinase Inhibitors
-
Vascular Endothelial Growth Factor A
-
Bevacizumab
-
Protein-Tyrosine Kinases
-
Receptors, Vascular Endothelial Growth Factor